CPHI & PMEC Shenzhen 2026 is set to welcome its most international audience to date, reflecting growing global interest in South China’s rapidly evolving pharmaceutical market and the technologies driving the next generation of healthcare innovation.
Taking place from 16-18 September 2026 at the Shenzhen Convention & Exhibition Center (SZCEC), China, this year’s event is expected to attract visitors from 140 countries, with strong attendance from C-suite executives and directors looking to identify new technologies, strategic partnerships and access one of the world’s fastest-growing pharmaceutical markets.
As Asia’s leading technology hub, Shenzhen has become a focal point for advances in AI-enabled drug development, smart manufacturing, biologics and digital healthcare. With China’s AI pharma market forecast to grow at a 41%+ CAGR, the city is playing an increasingly important role in the evolution of pharmaceutical innovation.
Anne Schumacher, Group Director of Events & Business Development, Informa Markets said: “This show offers an unrivalled opportunity for international businesses to connect with the people, technologies and partnerships shaping the next generation of pharma.”
“We’re delighted to be returning to Shenzhen and welcoming audiences with a keen interest in how AI and tech continue to evolve and deliver new and exciting innovations in our sector.”
As AI and digital technologies continue to transform pharmaceutical innovation, the 2026 exhibition will place a particular focus on emerging technologies through its new AI Tech & Contract Service zone. The Smart Manufacturing zone will further showcase the industry’s digital evolution, bringing together equipment manufacturers and service providers across intelligent production, automated logistics, inspection and testing, and IoT solutions.
Elsewhere, the Beauty & Cosmetics Supply Chain zone will connect visitors with regulated raw materials, precision manufacturing partners and advanced delivery technologies, supporting the development of compliant, market-ready products.
New opportunities will also be available across the Natural Supply zone, which will provide an end-to-end sourcing destination for plant-derived, animal-derived and microbial ingredients, alongside specialist partners spanning natural product development and manufacturing.
The show will feature more than 800 exhibitors, showcasing the latest developments across pharmaceutical ingredients, biotech, AI technology and contract services, finished dosage, packaging and drug delivery, pharmaceutical machinery, laboratory equipment, clean technology and more.
Beyond the exhibition floor, attendees will have the opportunity to connect with qualified buyers and suppliers through the Hosted Buyer Programme, creating opportunities to establish new relationships and accelerate business growth across international markets.
The event’s conference programme will further explore the trends shaping the future of pharmaceutical manufacturing, bringing together academic experts and industry leaders to discuss technological innovation, policy developments, and market opportunities across South China and beyond.
With South China’s pharmaceutical industry continuing to expand and demand for access to the Greater Bay Area increasing, CPHI & PMEC Shenzhen 2026 offers an unrivalled opportunity for international businesses to connect with the people, technologies and partnerships shaping the next generation of pharma.
Register now for your complimentary badge:
https://reg.cphi-china.cn/en/user/register
Learn more about the event:
https://www.cphi.com/china/en-gb/home.html
Contact us:
About Informa Markets
The CPHI portfolio includes 11 international events spanning Europe, the Americas, the Middle East, and Asia. Informa Markets creates platforms for industries and specialist markets to trade, innovate, and grow. As part of Informa PLC, it delivers more than 450 B2B events annually across key sectors including healthcare, life sciences, construction, and fashion. The company’s mission is to foster global communities, enabling meaningful connections and commercial success.
